Report Detail
Global RNAi for Therapeutic Market Insights, Forecast to 2025
- RnM3059644 |
- 05 March, 2019 |
- Global |
- 129 Pages |
- QYResearch |
- Other
The global RNAi for Therapeutic market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the RNAi for Therapeutic market based on company, product type, end user and key regions.
This report studies the global market size of RNAi for Therapeutic in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of RNAi for Therapeutic in these regions.
This research report categorizes the global RNAi for Therapeutic market by top players/brands, region, type and end user. This report also studies the global RNAi for Therapeutic market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead Research
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
Miragen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Arcturus Therapeutics
Ariz Biopharma
Celsion Corporation
Ascletis Pharmaceuticals
Market size by Product
siRNA
miRNA
shRNA
Market size by End User
Cancer
Cardiovascular
HBV
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global RNAi for Therapeutic market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of RNAi for Therapeutic market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global RNAi for Therapeutic companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of RNAi for Therapeutic submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of RNAi for Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of RNAi for Therapeutic market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 RNAi for Therapeutic Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global RNAi for Therapeutic Market Size Growth Rate by Product
- 1.4.2 siRNA
- 1.4.3 miRNA
- 1.4.4 shRNA
- 1.5 Market by End User
- 1.5.1 Global RNAi for Therapeutic Market Size Growth Rate by End User
- 1.5.2 Cancer
- 1.5.3 Cardiovascular
- 1.5.4 HBV
- 1.5.5 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global RNAi for Therapeutic Market Size
- 2.1.1 Global RNAi for Therapeutic Revenue 2014-2025
- 2.1.2 Global RNAi for Therapeutic Sales 2014-2025
- 2.2 RNAi for Therapeutic Growth Rate by Regions
- 2.2.1 Global RNAi for Therapeutic Sales by Regions
- 2.2.2 Global RNAi for Therapeutic Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 RNAi for Therapeutic Sales by Manufacturers
- 3.1.1 RNAi for Therapeutic Sales by Manufacturers
- 3.1.2 RNAi for Therapeutic Sales Market Share by Manufacturers
- 3.1.3 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
- 3.2 RNAi for Therapeutic Revenue by Manufacturers
- 3.2.1 RNAi for Therapeutic Revenue by Manufacturers (2014-2019)
- 3.2.2 RNAi for Therapeutic Revenue Share by Manufacturers (2014-2019)
- 3.3 RNAi for Therapeutic Price by Manufacturers
- 3.4 RNAi for Therapeutic Manufacturing Base Distribution, Product Types
- 3.4.1 RNAi for Therapeutic Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers RNAi for Therapeutic Product Type
- 3.4.3 Date of International Manufacturers Enter into RNAi for Therapeutic Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global RNAi for Therapeutic Sales by Product
- 4.2 Global RNAi for Therapeutic Revenue by Product
- 4.3 RNAi for Therapeutic Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global RNAi for Therapeutic Breakdown Data by End User
6 North America
- 6.1 North America RNAi for Therapeutic by Countries
- 6.1.1 North America RNAi for Therapeutic Sales by Countries
- 6.1.2 North America RNAi for Therapeutic Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America RNAi for Therapeutic by Product
- 6.3 North America RNAi for Therapeutic by End User
7 Europe
- 7.1 Europe RNAi for Therapeutic by Countries
- 7.1.1 Europe RNAi for Therapeutic Sales by Countries
- 7.1.2 Europe RNAi for Therapeutic Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe RNAi for Therapeutic by Product
- 7.3 Europe RNAi for Therapeutic by End User
8 Asia Pacific
- 8.1 Asia Pacific RNAi for Therapeutic by Countries
- 8.1.1 Asia Pacific RNAi for Therapeutic Sales by Countries
- 8.1.2 Asia Pacific RNAi for Therapeutic Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific RNAi for Therapeutic by Product
- 8.3 Asia Pacific RNAi for Therapeutic by End User
9 Central & South America
- 9.1 Central & South America RNAi for Therapeutic by Countries
- 9.1.1 Central & South America RNAi for Therapeutic Sales by Countries
- 9.1.2 Central & South America RNAi for Therapeutic Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America RNAi for Therapeutic by Product
- 9.3 Central & South America RNAi for Therapeutic by End User
10 Middle East and Africa
- 10.1 Middle East and Africa RNAi for Therapeutic by Countries
- 10.1.1 Middle East and Africa RNAi for Therapeutic Sales by Countries
- 10.1.2 Middle East and Africa RNAi for Therapeutic Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa RNAi for Therapeutic by Product
- 10.3 Middle East and Africa RNAi for Therapeutic by End User
11 Company Profiles
- 11.1 Alnylam Pharmaceuticals
- 11.1.1 Alnylam Pharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Products Offered
- 11.1.5 Alnylam Pharmaceuticals Recent Development
- 11.2 Arbutus Biopharma (Tekmira)
- 11.2.1 Arbutus Biopharma (Tekmira) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products Offered
- 11.2.5 Arbutus Biopharma (Tekmira) Recent Development
- 11.3 Arrowhead Research
- 11.3.1 Arrowhead Research Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Arrowhead Research RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Arrowhead Research RNAi for Therapeutic Products Offered
- 11.3.5 Arrowhead Research Recent Development
- 11.4 Dicerna Pharmaceuticals
- 11.4.1 Dicerna Pharmaceuticals Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Products Offered
- 11.4.5 Dicerna Pharmaceuticals Recent Development
- 11.5 Mirna Therapeutics
- 11.5.1 Mirna Therapeutics Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Mirna Therapeutics RNAi for Therapeutic Products Offered
- 11.5.5 Mirna Therapeutics Recent Development
- 11.6 Quark Pharmaceuticals
- 11.6.1 Quark Pharmaceuticals Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Quark Pharmaceuticals RNAi for Therapeutic Products Offered
- 11.6.5 Quark Pharmaceuticals Recent Development
- 11.7 RXi Pharmaceuticals
- 11.7.1 RXi Pharmaceuticals Company Details
- 11.7.2 Company Business Overview
- 11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 RXi Pharmaceuticals RNAi for Therapeutic Products Offered
- 11.7.5 RXi Pharmaceuticals Recent Development
- 11.8 Silence Therapeutics
- 11.8.1 Silence Therapeutics Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Silence Therapeutics RNAi for Therapeutic Products Offered
- 11.8.5 Silence Therapeutics Recent Development
- 11.9 Benitec Biopharma
- 11.9.1 Benitec Biopharma Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Benitec Biopharma RNAi for Therapeutic Products Offered
- 11.9.5 Benitec Biopharma Recent Development
- 11.10 Miragen Therapeutics
- 11.10.1 Miragen Therapeutics Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Miragen Therapeutics RNAi for Therapeutic Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Miragen Therapeutics RNAi for Therapeutic Products Offered
- 11.10.5 Miragen Therapeutics Recent Development
- 11.11 Sylentis
- 11.12 Gradalis
- 11.13 Sirnaomics
- 11.14 Silenseed
- 11.15 Arcturus Therapeutics
- 11.16 Ariz Biopharma
- 11.17 Celsion Corporation
- 11.18 Ascletis Pharmaceuticals
12 Future Forecast
- 12.1 RNAi for Therapeutic Market Forecast by Regions
- 12.1.1 Global RNAi for Therapeutic Sales Forecast by Regions 2019-2025
- 12.1.2 Global RNAi for Therapeutic Revenue Forecast by Regions 2019-2025
- 12.2 RNAi for Therapeutic Market Forecast by Product
- 12.2.1 Global RNAi for Therapeutic Sales Forecast by Product 2019-2025
- 12.2.2 Global RNAi for Therapeutic Revenue Forecast by Product 2019-2025
- 12.3 RNAi for Therapeutic Market Forecast by End User
- 12.4 North America RNAi for Therapeutic Forecast
- 12.5 Europe RNAi for Therapeutic Forecast
- 12.6 Asia Pacific RNAi for Therapeutic Forecast
- 12.7 Central & South America RNAi for Therapeutic Forecast
- 12.8 Middle East and Africa RNAi for Therapeutic Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 RNAi for Therapeutic Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on RNAi for Therapeutic . Industry analysis & Market Report on RNAi for Therapeutic is a syndicated market report, published as Global RNAi for Therapeutic Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of RNAi for Therapeutic market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
